Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Danshen Baibixiao is a **Traditional Chinese Medicine formula** that has been used clinically for the treatment of **psoriasis** for decades[1][3]. It is a **combination of multiple herbal ingredients**, with danshen (Salvia miltiorrhiza) as one principal component. The formula has demonstrated anti-psoriatic activity in preclinical models, particularly by ameliorating inflammation in imiquimod-induced psoriasis-like mice. Mechanistically, Danshen Baibixiao acts by **downregulating inflammatory cytokines** such as TNF-α, IL-17A, IL-23, IL-6, IL-1β, and IL-22. It also **suppresses activation of the NF-κB, STAT3, and MAPK signaling pathways** and modulates the IL-23/TH-17 immune axis, contributing to its anti-inflammatory and immunomodulatory effects relevant to psoriasis[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Danshen Baibixiao.